[HTML][HTML] Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline …
Annals of Oncology, 2020•Elsevier
Background In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.
1245A> C variant has been reported to be associated with shorter responses to first-line
androgen-deprivation therapy (ADT). Here, we evaluated the association between the
inherited HSD3B1 c. 1245A> C variant and outcomes from metastatic castration-resistant
prostate cancer (mCRPC) after first-line treatment with abiraterone (Abi) or enzalutamide
(Enza). Patients and methods Patients with mCRPC (n= 266) were enrolled from two centers …
1245A> C variant has been reported to be associated with shorter responses to first-line
androgen-deprivation therapy (ADT). Here, we evaluated the association between the
inherited HSD3B1 c. 1245A> C variant and outcomes from metastatic castration-resistant
prostate cancer (mCRPC) after first-line treatment with abiraterone (Abi) or enzalutamide
(Enza). Patients and methods Patients with mCRPC (n= 266) were enrolled from two centers …
Background
In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has been reported to be associated with shorter responses to first-line androgen-deprivation therapy (ADT). Here, we evaluated the association between the inherited HSD3B1 c.1245A>C variant and outcomes from metastatic castration-resistant prostate cancer (mCRPC) after first-line treatment with abiraterone (Abi) or enzalutamide (Enza).
Patients and methods
Patients with mCRPC (n = 266) were enrolled from two centers at the time of starting first-line Abi/Enza. Outcomes after Abi/Enza included best prostate-specific antigen (PSA) response, treatment duration, and overall survival (OS). Outcomes after first-line ADT were determined retrospectively, and included treatment duration and OS. As was prespecified, we compared patients with the homozygous variant HSD3B1 genotype (CC genotype) versus the combined group with the heterozygous (AC) and homozygous wild-type (AA) genotypes.
Results
Among the 266 patients, 22 (8.3%) were homozygous for the HSD3B1 variant (CC). The CC genotype had no association with PSA response rate; the median Abi/Enza treatment duration was 7.1 months for the CC group and 10.3 months for the AA/AC group (log rank P = 0.34). Patients with the CC genotype had significantly worse OS, with median survival at 23.6 months for the CC group and 30.7 months for the AA/AC group (log rank P = 0.02). In multivariable analysis adjusting for age, Gleason score, PSA, prior chemotherapy, and M1 disease, the association between the CC genotype and OS remained significant (hazard ratio 1.78, 95% confidence interval 1.03–3.07, P = 0.04). Poor outcome after first-line ADT in the CC group was also observed when evaluating retrospective ADT duration data for the same combined cohort.
Conclusions
In this large two-center study evaluating the HSD3B1 c.1245 genotype and outcomes after first-line Abi/Enza, homozygous variant (CC) HSD3B1 genotype was associated with worse outcomes. Novel therapeutic strategies are needed to enable treatment selection based on this genetic marker.
Elsevier
